Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTISAVE trial of glenzocimab added to standard care for acute ischemic stroke
MOH_2022-09-14_012050Phase 3Not yet recruiting
- Sponsor
- Acticor Biotech
- Start
- Sep 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing glenzocimab + standard care with placebo + standard care (2 arms). Planned start Sep 2022; status: not yet recruiting.
02
Drugs
glenzocimab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on MOH_2022-09-14_012050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-09-14_012050.